Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape.
Immunology
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
20 Jan 2023
20 Jan 2023
Historique:
received:
27
09
2022
revised:
21
10
2022
accepted:
01
12
2022
pubmed:
13
12
2022
medline:
13
12
2022
entrez:
12
12
2022
Statut:
ppublish
Résumé
Memory B cells (MBCs) generate rapid antibody responses upon secondary encounter with a pathogen. Here, we investigated the kinetics, avidity, and cross-reactivity of serum antibodies and MBCs in 155 SARS-CoV-2 infected and vaccinated individuals over a 16-month time frame. SARS-CoV-2-specific MBCs and serum antibodies reached steady-state titers with comparable kinetics in infected and vaccinated individuals. Whereas MBCs of infected individuals targeted both prefusion and postfusion Spike (S), most vaccine-elicited MBCs were specific for prefusion S, consistent with the use of prefusion-stabilized S in mRNA vaccines. Furthermore, a large fraction of MBCs recognizing postfusion S cross-reacted with human betacoronaviruses. The avidity of MBC-derived and serum antibodies increased over time resulting in enhanced resilience to viral escape by SARS-CoV-2 variants, including Omicron BA.1 and BA.2 sublineages, albeit only partially for BA.4 and BA.5 sublineages. Overall, the maturation of high-affinity and broadly reactive MBCs provides the basis for effective recall responses to future SARS-CoV-2 variants.
Identifiants
pubmed: 36507220
doi: 10.1016/j.isci.2022.105726
pii: S2589-0042(22)01999-X
pmc: PMC9721160
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105726Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
R.M., J.B., C.S.-F., I.B., F.M., K.C., N.S., G.L., C.S., E.C., E.A.D.J., J.R.D., N.C., C.H.-D., A.T., A.A., H.W.V., A.L., D.C., and L.Pi. are or were employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. C.G. is an external scientific consultant to Humabs BioMed SA. The other authors declare no competing interests.
Références
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Science. 2022 Aug 19;377(6608):890-894
pubmed: 35857529
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243
pubmed: 32269081
Cell. 2022 Mar 3;185(5):872-880.e3
pubmed: 35123650
Science. 2021 Sep 03;373(6559):1109-1116
pubmed: 34344823
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Sci Immunol. 2022 Dec 23;7(78):eadf1421
pubmed: 36356052
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Nature. 2021 Apr;592(7853):283-289
pubmed: 33524990
Nature. 2021 Oct;598(7880):342-347
pubmed: 34464958
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Science. 2022 Nov 11;378(6620):619-627
pubmed: 36264829
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Nature. 2021 Sep;597(7874):97-102
pubmed: 34261126
Cell. 2022 Apr 28;185(9):1588-1601.e14
pubmed: 35413241
Immunity. 2021 Dec 14;54(12):2893-2907.e5
pubmed: 34614412
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Emerg Microbes Infect. 2022 Dec;11(1):1524-1536
pubmed: 35608053
Eur J Immunol. 2009 May;39(5):1260-70
pubmed: 19404981
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Cell Rep. 2021 Mar 23;34(12):108890
pubmed: 33713594
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2022 Feb 25;375(6583):864-868
pubmed: 35076256
Science. 2021 Mar 25;:
pubmed: 33766944
Clin Microbiol Infect. 2021 Sep;27(9):1349.e1-1349.e6
pubmed: 33975009
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Sci Immunol. 2022 Jul 29;7(73):eabq3511
pubmed: 35549299
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
Cell. 2022 May 26;185(11):1875-1887.e8
pubmed: 35523182